S. Ohmura

EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism

This study identifies how the EWS::FLI1-DHX9 interaction influences R-loop metabolism and Ewing sarcoma sensitivity to DNA topoisomerase 1 inhibitors.

Chromosome 8 gain drives cancer progression by hijacking the translation factor 4E-BP1 sensitizing for targeted CDK4/6 inhibition

This study identifies chr8 gains and 4E-BP1 expression as prognostic markers in Ewing sarcoma, showing they drive cancer progression by promoting proliferation and sensitizing to CDK4/6 inhibitors.

Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma

This paper develops a gene expression strategy that exploits neomorphic DNA-binding of fusion transcription factors in pediatric sarcomas to deliver therapeutic payloads with tumor-specific efficacy.

Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

This study identifies RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma, showing its overexpression correlates with poor survival and that its inhibition reduces tumor growth and overcomes chemoresistance.

Systems biology analysis identifies TCF7L1 as a key regulator of metastasis in Ewing sarcoma

Cooperation of dominant oncogenes with regulatory germline variants shapes clinical outcomes in childhood cancer

This study shows how a dominant oncogene and regulatory germline variants together influence tumor growth, survival, and drug response in Ewing sarcoma.

Oncogenic hijacking of a developmental transcription factor evokes therapeutic vulnerability for ROS-induction in Ewing sarcoma

The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.

Biomarker-based outcome prediction in prostate adenocarcinoma depends on the TMPRSS2-ERG status

This study identifies subtype-specific prognostic biomarkers in prostate adenocarcinoma, showing that their prognostic value depends on TMPRSS2-ERG fusion status.

SOX2 expression identifies Ewing sarcoma patients with high risk for tumor relapse and poor survival

Targeting the CALCB/RAMP1-axis inhibits growth of Ewing sarcoma

This study identifies CALCB as a direct EWSR1-FLI1 target in Ewing sarcoma and shows that targeting the CALCB/RAMP1-axis inhibits tumor growth.

Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma

This study identifies AMPD2 as a prognostic biomarker for undifferentiated pleomorphic sarcoma using transcriptome analysis, immunohistochemistry, and functional assays.

Systematic identification of cancer-specific MHC-binding peptides with RAVEN

The paper introduces RAVEN, a software tool that identifies cancer-specific genes encoding MHC-affine peptides from gene expression data, validated across 50 cancer types.

Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets

This study identifies ATP1A1, BCL11B, and GLG1 as specific immunohistochemical markers for Ewing sarcoma, offering high specificity for diagnosis.